At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Infliximab 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)
In Brief
An observational study evaluating Infliximab for Crohn Disease. Completed, enrolled 15 participants.
Detailed Summary
This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartNov 2012
Primary CompletionSep 2015
TodayJul 2026
First PostedMay 9, 2011
Enrollment StartNov 28, 2012
Primary CompletionSep 28, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.1 years ago
Interventions
Infliximabdrug
Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.